OPN polymorphism is related to the chemotherapy response and prognosis in advanced NSCLC

International Journal of Genomics

Volumn 2014, Issue , 2014, Pages

  Hao, Yanzhang ^a   Liu, Jianwei ^b   Wang, Ping ^a   Wang, Feng ^a   Yu, Zeshun ^a   Li, Mianli ^a   Chen, Shaoshui ^a   Ning, Fangling ^a  

^a Affiliated Hospital of Binzhou Medical University   (China)

^b The Affiliated Hospital of Binzhou Medical University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DNA; OSTEOPONTIN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ANALYZER; GENETIC ASSOCIATION; GENOTYPE; HEREDITY; HUMAN; HUMAN TISSUE; INOPERABLE CANCER; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSTICS; OVERALL SURVIVAL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL LUNG CARCINOMA; TREATMENT RESPONSE;

EID: 84921352684     PISSN: 2314436X     EISSN: 23144378     Source Type: Journal    
DOI: 10.1155/2014/846142     Document Type: Article

References (31)

1. C. I. Kocaturk, M. Z. Gunluoglu, L. Cansever, I. S. Dincer, and M. A. Bedirhan, "Prognosis in patients with non-small cell lung cancer and satellite tumors, " Thoracic and Cardiovascular Surgeon, vol. 59, no. 6, pp. 360-363, 2011.
2. G. Friedel, V. Steger, T. Kyriss, J. Zoller, and H. Toomes, "Prognosis in N2 NSCLC, " Lung Cancer, vol. 45, no. 2, pp. S45- S53, 2004.
3. F. Honeckera, U. Weddingb, and C. Bokemeyer, "Chemotherapy in elderly patients with advanced lung cancer part II: Treatment of Non-Small Cell Lung Cancer (NSCLC), " Onkologie, vol. 27, no. 6, pp. 583-588, 2004.
4. R. Rosell, M. Cobo, D. Isla et al., "Applications of genomics in NSCLC, " Lung Cancer, vol. 50, no. 2, pp. S33-S40, 2005.
5. C. Gridelli, P. Maione, A. Rossi, G. Palazzolo, G. Colantuoni, and E. Rossi, "Management of unfit older patients with advanced NSCLC, " Cancer Treatment Reviews, vol. 35, no. 6, pp. 517-521, 2009.
6. M. Inoue and M. L. Shinohara, "Intracellular osteopontin (iOPN) and immunity, " Immunologic Research, vol. 49, no. 1-3, pp. 160-172, 2011.
7. G. F. Weber, G. S. Lett, and N. C. Haubein, "Categoricalmetaanalysis of osteopontin as a clinical cancer marker, " Oncology Reports, vol. 25, no. 2, pp. 433-441, 2011.
8. H. Wang, X. Wang, and C. Tang, "Osteopontin expression in nasopharyngeal carcinoma: its relevance to the clinical stage of the disease, " Journal of Cancer Research and Therapeutics, vol. 7, no. 2, pp. 138-142, 2011.
9. B. Zhao, T. Sun, F. Meng et al., "Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer, " Journal of Cancer Research and Clinical Oncology, vol. 137, no. 7, pp. 1061-1070, 2011.
10. D. Cao, Z. Li, X. Jiang et al., "Osteopontinaspotential biomarker and therapeutic target in gastric and liver cancers, " World Journal of Gastroenterology, vol. 18, no. 30, pp. 3923-3930, 2012.
11. L. Yi, X.Hou, J. Zhou et al., "HIF-1Kappa genetic variants and protein expression confer the susceptibility and prognosis of gliomas, " NeuroMolecular Medicine, 2014.
12. A. F. Chambers, S. M. Wilson, N. Kerkvliet, F. P. O'Malley, J. F. Harris, and A. G. Casson, "Osteopontin expression in lung cancer, " Lung Cancer, vol. 15, no. 3, pp. 311-323, 1996.
13. V. Donati, L. Boldrini, M. Dell'Omodarme et al., "Osteopontin expression and prognostic significance in non-small cell lung cancer, " Clinical Cancer Research, vol. 11, no. 18, pp. 6459-6465, 2005.
14. X.W. Hou, R. Q. Yang, Y. G. Zhong, W. Gao, S. P. Sun, and N. F. Wang, "G501C polymorphism of the oxidized LDL receptor gene is associated with albuminuria in Chinese essential hypertension patients, " Genetics and Molecular Research, vol. 10, no. 4, 2011.
15. S. Schneider, J. Yochim, J. Brabender et al., "Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer, " Clinical Cancer Research, vol. 10, no. 5, pp. 1588-1596, 2004.
16. Z. Hu, D. Lin, J. Yuan et al., "Overexpression of osteopontin is associated with more aggressive phenotypes in human nonsmall cell lung cancer, " Clinical Cancer Research, vol. 11, no. 13, pp. 4646-4652, 2005.
17. F.Wu, N. Hu, Y. Li, B. Bian, G. Xu, and Y. Zheng, "Galectin-3 genetic variants are associatedwith platinum-based chemotherapy response and prognosis in patients with NSCLC, " Cellular Oncology, vol. 35, no. 3, pp. 175-180, 2012.
18. Y. Jin, D. Y. Tong, L. Y. Tang et al., "Expressions of Osteopontin (OPN), alphanubeta3 and Pim-1 Associated with Poor Prognosis in Non-small Cell Lung Cancer (NSCLC), " Chinese Journal of Cancer Research, vol. 24, no. 2, pp. 103-108, 2012.
19. Q. Dong, X. Zhang, Y. Zhao et al., "Osteopontin promoter polymorphisms at locus -443 significantly affect the metastasis and prognosis of human hepatocellular carcinoma, " Hepatology, vol. 57, no. 3, pp. 1024-1034, 2013.
20. H. Xu, X. Hou, N. Wang et al., "Gender-specific effect of estrogen receptor-1 gene polymorphisms in coronary artery disease and its angiographic severity in Chinese population, " Clinica Chimica Acta, vol. 395, no. 1-2, pp. 130-133, 2008.
21. J. Schultz, P. Lorenz, S. M. Ibrahim, G. Kundt, G. Gross, and M. Kunz, "The functional -443T/C osteopontin promoter polymorphism influences osteopontin gene expression in melanoma cells via binding of c-Myb transcription factor, " Molecular Carcinogenesis, vol. 48, no. 1, pp. 14-23, 2009.
22. G. Mu, H. Wang, Z. Cai, and H. Ji, "OPN -443C>T genetic polymorphism and tumor OPN expression are associated with the risk and clinical features of papillary thyroid cancer in a Chinese cohort, " Cellular Physiology and Biochemistry, vol. 32, no. 1, pp. 171-179, 2013.
23. X. Hou, Z. Hu, X. Huang et al., "Serum osteopontin, but not OPN gene polymorphism, is associated with LVH in essential hypertensive patients, " Journal of Molecular Medicine, vol. 92, no. 5, pp. 487-495, 2014.
24. O. Shaker, A. El-Shehaby, S. Fayez, A. Zahra, S.Marzouk, and M. E. Raziky, "Osteopontin gene polymorphisms as predictors for the efficacy of interferon therapy in chronic hepatitisCEgyptian patients with genotype 4, " Cell Biochemistry and Function, 2013.
25. O. G. Shaker, N. A. H. Sadik, and A. El-Dessouki, "Singlenucleotide polymorphism in the promoter region of the osteopontin gene at nucleotide -443 as a marker predicting the efficacy of pegylated interferon/ribavirin-therapy in Egyptians patients with chronic hepatitis C, " Human Immunology, vol. 73, no. 10, pp. 1039-1045, 2012.
26. X.W. Hou, L. F.Wang, N. Wang et al., "The G501C polymorphism of oxidized LDL receptor gene [OLR-1] is associated with susceptibility and serum C-reactive protein concentration in Chinese essential hypertensives, " Clinica Chimica Acta, vol. 388, no. 1-2, pp. 200-203, 2008.
27. M. Naito, A.Matsui, M. Inao et al., "SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C, " Journal of Gastroenterology, vol. 40, no. 4, pp. 381-388, 2005.
28. X. Hou, N. Appleby, T. Fuentes et al., "Isolation, characterization, and spatial distribution of cardiac progenitor cells in the sheep heart, " Journal of Clinical & Experimental Cardiology, p. S6, 2012.
29. F. Ceccarelli, S. D'Alfonso, C. Perricone et al., "The role of eight polymorphisms in three candidate genes in determining the susceptibility, phenotype, and response to anti-TNF therapy in patients with rheumatoid arthritis, " Clinical and Experimental Rheumatology, vol. 30, no. 6, pp. 939-942, 2012.
30. Y. Chen, H. Liu, W. Wu, Y. Li, and J. Li, "Osteopontin genetic variants are associated with overall survival in advanced nonsmall- cell lung cancer patients and bone metastasis, " Journal of Experimental and Clinical Cancer Research, vol. 32, no. 1, article 45, 2013.
31. X. Hou, Z. Hu, H. Xu et al., "Advanced glycation endproducts trigger autophagy in cadiomyocyte via RAGE/PI3K/AKT/mTOR pathway, " Cardiovascular Diabetology, vol. 13, p. 78, 2014.